ILLINOIS

Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023

Retrieved on: 
Wednesday, April 10, 2024
HTC, CER, Farmer, Pressure, Farm, Growth, Nutrition, Biologicals, Crop protection, Flower, Shanghai Stock Exchange, Syngenta, Acquisition, IPO, Seed, MAP, Soil, Huludao, Fine chemical

Full-year sales of Syngenta Crop Protection were 5 percent lower at $15.5 billion after exceptional growth in the previous year.

Key Points: 
  • Full-year sales of Syngenta Crop Protection were 5 percent lower at $15.5 billion after exceptional growth in the previous year.
  • ADAMA sales decreased 17 percent to $5.6 billion for the full year 2023, with significant channel destocking, particularly in the Americas, affecting the comparison.
  • Syngenta Seeds sales grew 2 percent to $4.8 billion in the full year 2023 in an overall growing seeds market.
  • Sales of Syngenta Group China, consisting of the Group’s Seeds, Crop Protection, Crop Nutrition, MAP and digital activities in China, grew 11 percent to $9.6 billion in the full year 2023.

Allstate, Sompo & Lloyd's Answer Your GenAI Questions to Build Your AI Foundation in Claims

Retrieved on: 
Thursday, April 4, 2024
Automation, Reward, Tune, Allstate, Algorithm, AI, Potential

Chicago, Illinois--(Newsfile Corp. - April 4, 2024) - AI was recently the latest 'shiny new toy' that enabled claims departments to delve into automation.

Key Points: 
  • Chicago, Illinois--(Newsfile Corp. - April 4, 2024) - AI was recently the latest 'shiny new toy' that enabled claims departments to delve into automation.
  • Then, before we have even got up to speed, GenAI came on the scene to revolutionize claims from streamlining claims processing, to data insight, to fraud detection.
  • However, we have a lot of questions to answer before we can build a foundation for AI usage and really see these benefits.
  • Tune into our next webinar to get your answers - From AI to GenAI: Unlock the Potential for Claims (April 16th, 11am EST or On Demand)
    Discover where AI and GenAI can most benefit you, and start seeing the impact now:
    Develop your AI roadmap and decide on your comfort zone: Have impact with AI now, keeping human in the loop, and be ready to hit the ground running when AI matures enough to be scalable and really change the claims game
    Prepare with your data experts: It's not just about strategizing and deciding where to deploy AI, work with your data team to create an accessible data warehouse full of rich data that will train and fuel your AI algorithms
    Let's get started: Implement GenAI where these is low risk but high reward - free up adjusters with document summaries, automate claims allocation, identify risk trends and make huge efficiency gains
    Our panellists have real life experience and learnings from pushing forward with AI innovations:
    Don Jones, SVP Claims Design & Delivery, Allstate
    Understand AI, decide where you need it, and get started now so you're not behind by the next innovation.

Blue Label Cigar Lounge Opens It's Flagship Lounge Outside of Chicago

Retrieved on: 
Wednesday, April 3, 2024
Sculpture, Skull, System, Environment

Luxury private cigar lounge sets their sights on key demographic.

Key Points: 
  • Lockport, Illinois--(Newsfile Corp. - April 3, 2024) - This spring, Blue Label Cigar Lounge, a luxury private cigar lounge, announced the completion of the opening of its first location, serving as the company's flagship facility.
  • The main members salon at Blue Label Cigar Lounge.
  • To view an enhanced version of this graphic, please visit:
    On the company's recent milestone, Blue Label Cigar Lounge President William Egbert Jr. said, "We set out to redefine the luxury cigar lounge space while offering our members a truly unique environment.
  • A juvenile T-Rex skull provides a unique focal point for guests at Blue Label Cigar Lounge.

SEC Charges 17 Individuals in $300 Million Crypto-Asset Ponzi Scheme Targeting the Latino Community

Retrieved on: 
Thursday, March 14, 2024
District court, Security (finance), Investment, Spouse, Cryptocurrency

Today’s complaint follows the SEC’s successful emergency action in September 2022 that halted the CryptoFX scheme and charged its two main principals, Mauricio Chavez and Giorgio Benvenuto.

Key Points: 
  • Today’s complaint follows the SEC’s successful emergency action in September 2022 that halted the CryptoFX scheme and charged its two main principals, Mauricio Chavez and Giorgio Benvenuto.
  • “Our efforts bore significant fruit as the charges and allegations today demonstrate.”
    According to the SEC’s complaint, CryptoFX purported to trade in crypto asset and foreign exchange markets for investors but was in reality a Ponzi scheme.
  • The complaint alleges that CryptoFX raised $300 million from investors but did not use most of the funds for its claimed trading purposes.
  • The SEC encourages investors to check the backgrounds of anyone selling or offering them an investment using the free and simple search tool on Investor.gov .

Critical Concerns Around Compliance and Geopolitical Uncertainty Featured in Redwood’s Cross-Border Index

Retrieved on: 
Tuesday, April 9, 2024
Carrier Global, Hope, Commerce, Investment, Drug

The situation is exacerbated by the strengthening Mexican peso against the US dollar, which may undermine the competitiveness of Mexican exports.

Key Points: 
  • The situation is exacerbated by the strengthening Mexican peso against the US dollar, which may undermine the competitiveness of Mexican exports.
  • "Compliance and trade regulations, such as the 'Carta Porte,' are crucial to ensuring the swift movement of goods across the border," said Jordan Dewart, President, Redwood Mexico.
  • "A balanced approach that prioritizes trade efficiency while addressing immigration concerns responsibly is going to be crucial to keep cross-border trade flowing seamlessly."
  • "It's a critical moment for us to seek innovative solutions and maintain flexibility to adapt quickly to changing market demands."

Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders

Retrieved on: 
Tuesday, April 9, 2024
Cell, Recycling, PD, Patient, Glucocerebrosidase, Doctor of Philosophy, Alpha-synuclein, Trial of the century, Protein, Neuron, Safety, Pharmacokinetics, Lysosome

CHICAGO, April 09, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD). VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).

Key Points: 
  • VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).
  • “VQ-101 demonstrated promising efficacy, safety, pharmacokinetics, and target engagement in preclinical studies.
  • Mutations in GBA1 are the most common genetic risk factor for PD, representing approximately 10% of patients with PD worldwide.
  • In developing VQ-101, Vanqua is adopting a precision-medicine approach that focuses initially on patients with GBA-PD, the largest genetically defined segment of PD.

Second Fisher House Dedicated at the Audie Murphy VA Campus of South Texas VA

Retrieved on: 
Friday, April 5, 2024
Audie Murphy, Veterans' affairs, Partnership, Health, Patient, Audie, House, Fisher House, Amazon Web Services, Road, Hospital, Fisher House Foundation, Navy

San Antonio, Texas, April 05, 2024 (GLOBE NEWSWIRE) -- A second Fisher House was dedicated today at the Audie L. Murphy Memorial Veterans’ Hospital by Executive Director Dr. Julianne Flynn and President of Fisher House Foundation David A. Coker.

Key Points: 
  • San Antonio, Texas, April 05, 2024 (GLOBE NEWSWIRE) -- A second Fisher House was dedicated today at the Audie L. Murphy Memorial Veterans’ Hospital by Executive Director Dr. Julianne Flynn and President of Fisher House Foundation David A. Coker.
  • The new home will double the South Texas VA Health Care System’s capacity to offer a home away from home to the families of Veterans who are inpatients at the Audie Murphy VA Medical Center.
  • Fisher House Foundation is on the Road to 100 Fisher Houses with projects underway in Memphis, Tennessee; Detroit, Michigan; and the 100th Fisher House, which will be in North Chicago, Illinois.
  • The new South Texas VA Fisher House has 16 wheelchair-accessible suites; a spacious kitchen; large communal living, dining, and family rooms; a laundry room; and a shared patio.

Fulcrum GT Earns Recognition for Innovation and Accelerated Growth

Retrieved on: 
Friday, April 5, 2024
Editorial, Culture, Organization, Database, Growth, MIC, Inc., Corporate services, Risk, Gold, AI, Hope, Regionals, Taco Bell, Most, Fast, Geography, Fulcrum

CHICAGO, April 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum GT , provider of the leading digital business platform for legal and professional services firms, is proud to share two recent public rankings recognizing the company for its achievements in innovation and growth.

Key Points: 
  • CHICAGO, April 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum GT , provider of the leading digital business platform for legal and professional services firms, is proud to share two recent public rankings recognizing the company for its achievements in innovation and growth.
  • “The entire team at Fulcrum works hard every day to create and deliver innovative solutions that support the evolving needs of our clients.
  • Inclusion on these rankings is a testament to that effort and to the resulting growth we’ve achieved.
  • Fulcrum earned its rank with a two-year revenue growth from 2020 to 2022 of 197%, while other companies on the 2024 Inc. 5000 Regionals: Midwest list had an average growth rate of 134.06%.

Fanatics Sportsbook Launches Today in Illinois

Retrieved on: 
Friday, April 5, 2024
Discover, Sport, Hawthorne Race Course, News, Acquisition, Gambling, IOS, Android

CICERO, Ill., April 05, 2024 (GLOBE NEWSWIRE) -- Fanatics Betting and Gaming, a subsidiary of Fanatics Holdings Inc, a global digital sports platform, launched the Fanatics Sportsbook today in Illinois.

Key Points: 
  • CICERO, Ill., April 05, 2024 (GLOBE NEWSWIRE) -- Fanatics Betting and Gaming, a subsidiary of Fanatics Holdings Inc, a global digital sports platform, launched the Fanatics Sportsbook today in Illinois.
  • Sports fans living in and visiting Illinois will be able to download the Fanatics Sportsbook on iOS and Android and begin their Fanatics Sportsbook experience.
  • Today in Illinois, PointsBet customers' username, password, account balance, rewards points and responsible gaming settings will be automatically migrated to the Fanatics Sportsbook.
  • The Fanatics Sportsbook makes being a fan easy with fast signup, easy betting, transparent withdrawals and is disrupting the sports betting industry with the following new features:
    Building a better sportsbook: The Fanatics Sportsbook app was built natively on iOS and Android .

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Retrieved on: 
Friday, April 5, 2024
NMIBC, Patient, Mouse, Cancer, Bladder cancer, LIPO, Pembrolizumab, Society, ASCO, Therapy, Physician

Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .

Key Points: 
  • Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .
  • Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer.
  • Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC).
  • Dr. Michael Chancellor, Lipella’s Chief Medical Officer, emphasized the significance of this milestone for advancing the company’s LP-50 program.